Fundraising FoxYsios Capital — 2014 Investments
1 investments dated 2014 · listed companies and verified rows first · show all
A biopharmaceutical company developing an artificial intelligence infrastructure platform designed for on-premises deployment in biotechnology and pharmaceutical research environments, serving biotech firms and pharma companies seeking secure access to advanced AI capabilities while retaining control over proprietary biological data; the company is also evaluating strategic alternatives for its legacy mesenchymal stem cell secretome assets after discontinuing its lead rare eye disease therapeutic program.
BiotechArlington, US
Justin Hanes(Director)inKevin Pojasek(Executive Officer)inDarius Kharabi(Executive Officer)inTodd Bazemore(Executive Officer)inMark Iwicki(Executive Officer, Director)inMary Reumuth(Executive Officer)in
Co-investorsLongitude CapitalSR One Capital ManagementWellington ManagementAtlas VentureLux CapitalRA Capital+1 more
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.